Outcomes According to Appropriate Use Group
| Variable | Entire cohort (n = 1,511) | Appropriate/uncertain (n = 823; 54.5%) | Inappropriate (n = 688; 45.5%) | P |
| Outcome events (n) | ||||
| MACE (cardiac death or MI) | 22 (1.5%) | 20 (2.4%) | 2 (0.3%) | <0.001* |
| Cardiac death | 12 (0.8%) | 12 (1.5%) | 0 (0%) | 0.001* |
| Myocardial infarction | 11 (0.7%) | 9 (1.1%) | 2 (0.3%) | 0.08* |
| REV within 6 mo | 29 (1.9%) | 19 (2.3%) | 10 (1.5%) | 0.23† |
| Median predicted probabilities of events (%) | ||||
| MACE: cardiac death or MI | 0.41 (0.1–1.13) | 0.59 (0.24–1.55) | 0.27 (0.14–0.77) | <0.001‡ |
| Annualized MACE* | 0.18 (0.08–0.50) | 0.26 (0.10–0.69) | 0.12 (0.06–0.34) | <0.001‡ |
| 6-mo REV† | 0.60 (0.27–1.49) | 0.82 (0.34–1.99) | 0.44 (0.21–1.10) | <0.001‡ |
| Median radiation exposure and LAR | ||||
| Rest 99mTc dose (MBq) | 374 (363–389) | 374 (363–389) | 374 (363–389) | 0.77‡ |
| Stress 99mTc dose (MBq) | 1,280 (1,228–1,336) | 1,277 (1,228–1,328) | 1,284 (1,232–1,343) | 0.21‡ |
| Total 99mTc dose (MBq) | 1,654 (1,598–1,721) | 1,654 (1,595–1,717) | 1,658 (1,598–1,728) | 0.39‡ |
| Effective dose (mSv) | 13.5 (13.1–14.0) | 13.5 (13.1–14.0) | 13.5 (13.1–14.1) | 0.52‡ |
| LAR of cancer (%) | 0.07 (0.05–0.09) | 0.06 (0.04–0.08) | 0.08 (0.07–0.10) | <0.001‡ |
| Median benefit-to-risk ratio | ||||
| Predicted MACE-to-LAR ratio | 2.6 (0.9–9.0) | 4.3 (1.6–15.4) | 1.5 (0.7–4.6) | <0.001‡ |
| 6-mo-REV–to–LAR ratio | 9.84 (3.6–27.2) | 15.5 (5.7–39.1) | 5.4 (2.5–14.5) | <0.001‡ |